Module

Antiretroviral Selection in Treatment-Naive Patients

Source: When to Start, What to Use: A Master Class in the Use of First-Line Antiretroviral Therapy

Antiretroviral Selection in Treatment-Naive Patients

Faculty:
Paul E. Sax, MD

CME CREDIT INFORMATION

Release Date: 12/11/07

Expiration Date: 12/10/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.4 contact hours (0.14 CEUs)

Registered Nurses: 1.4 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the recommended antiretroviral regimens for antiretroviral-naive, HIV-infected individuals as outlined in treatment guidelines
Discuss clinical trial data and host factors that are important to consider when choosing an initial regimen
Evaluate treatment strategies for the management of antiretroviral-naive patients

Topics covered include:

Introduction
Goals of Antiretroviral Therapy and Strategies for Successful Treatment
Selecting the Optimal Initial Antiretroviral Regimen
Selecting the Optimal NRTI Pair: Tenofovir/Emtricitabine
Selecting the Optimal NRTI Pair: Abacavir Plus Lamivudine
Selecting the Optimal NRTI Pair: Zidovudine Plus Lamivudine
Selecting the Optimal First-Line Regimen: Choosing Between an NNRTI or a Boosted PI
Selecting the Optimal NNRTI: Efavirenz vs Nevirapine
Selecting the Optimal Boosted PI: Lopinavir/Ritonavir
Selecting the Optimal Boosted PI: Atazanavir/Ritonavir
Selecting the Optimal Boosted PI: Fosamprenavir/Ritonavir
Selecting the Optimal Boosted PI: Saquinavir/Ritonavir
Novel Treatment Approaches
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.